51 results about "Virus antigen" patented technology

The utility model relates to the field of antigen detection kits, and discloses an infectious bovine rhinotracheitis virus antigen detection kit which comprises a box body, a roller is rotatably connected to the bottom side in the box body, a clamping groove is formed in the upper side of the roller, a clamping pin is connected to the clamping groove in a clamping mode, and a placing table is fixedly connected to the upper side of the clamping pin. A plurality of swab placing grooves, an extraction tube placing groove and a detection card placing groove are respectively formed in the upper side of the placing table, the plurality of swab placing grooves, the extraction tube placing groove and the detection card placing groove are distributed in a circumferential array, and sampling swabs are arranged on the inner sides of the plurality of swab placing grooves; according to the utility model, a plurality of groups of sampling swabs, sample extraction tubes and antigen detection cards which are distributed in a circumferential array manner are placed on the placement table, so that when sampling personnel go to cattle for sampling one by one, the sampling personnel can rotate to detection materials such as the next group of antigen detection cards and the like only by pressing down the push rod and switching the angle of the placement table, and the operation is convenient and the use is simple.

The invention relates to a detection kit for nasopharynx cancer diagnosis and screening, which comprises an immunochromatography detection card, and the immunochromatography detection card comprises a reagent for detecting EB virus antigen and antibody through a colloidal gold labeling method. The invention also relates to application of the detection card and the EB virus antigen-antibody in preparation of a detection kit or a detection card for nasopharynx cancer diagnosis and screening.

The invention belongs to the technical field of poultry disease prevention and treatment, and discloses application of a rhizoma kaempferiae extract in preparation of a medicine for resisting avian infectious bronchitis virus. The rhizoma kaempferiae extract is prepared by taking rhizoma kaempferiae as a raw material and ethanol as an extraction solvent through extraction, filtration and concentration. Experimental results show that the rhizoma kaempferiae extract has no obvious toxicity to chick embryos within a certain dosage range; after the chicken embryo is infected with the infectious bronchitis virus, the survival rate of the chicken embryo can be improved by treating the chicken embryo with different doses of the rhizoma kaempferiae extract, and the rhizoma kaempferiae extract can reduce the virus antigen expression level and virus copy number in the liver tissue and allantoic fluid of the chicken embryo, so that the chicken embryo has prevention and treatment effects on infectious bronchitis virus infection. The rhizoma kaempferiae extract has the advantages of easily available raw materials, simple process and low cost, and is suitable for popularization and application.

The invention provides a linear epitope of an African swine fever virus CP312R protein. The amino acid sequence of the linear epitope is SEQ ID NO: 1 or SEQ ID NO: 2. The antigen epitope polypeptide provided by the invention has good antigen specificity and immunoreactivity. The polypeptide can be efficiently combined with an African swine fever virus specific antibody, background interference is low, cross reaction is small, and detection sensitivity and accuracy are remarkably improved. By using the polypeptide as a coating antigen in immunodetection methods such as ELISA or colloidal gold immunochromatography, rapid and accurate detection of ASFV infection can be realized, and the detection result is stable and reliable. Compared with a traditional whole virus antigen or a crude extract antigen, the epitope polypeptide has the advantages of being simple and convenient to prepare, small in batch difference, high in safety and the like, and is suitable for ASFV serological monitoring and diagnosis application.

The present disclosure is directed to antibodies binding to and neutralizing henipavirus and methods for use thereof. Thus, in accordance with the present disclosure, there is provided a method of detecting a henipavirus infection in a subject comprising (a) contacting a sample from said subject with an antibody or antibody fragment having clone-paired heavy and light chain CDR sequences from Tables 3 and 4, respectively; and (b) detecting henipavirus in said sample by binding of said antibody or antibody fragment to a henipavirus antigen in said sample.

The invention relates to the technical field of genetic engineering, in particular to identification of a new insertion site of a self-assembled protein cage nanoparticle antigen epitope and application of the new insertion site in vaccine preparation. It is found that a foot-and-mouth disease virus antigen epitope is inserted between 62nd-63rd amino acids of an Encapsulin protein fragment after amino acid sequence modification, and / or the 62nd-63rd amino acids are replaced with the foot-and-mouth disease virus antigen epitope, efficient and soluble expression of a target antigen in escherichia coli can be achieved, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized anti-foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a foot-and-mouth disease vaccine.

The invention belongs to the technical field of nano-antibodies, and particularly relates to a nano-antibody for resisting H1N1 influenza virus NA protein as well as a preparation method and application of the nano-antibody. The method comprises the following steps: by taking A / Puerto Rick / 8 / 34 (H1N1) influenza virus as a research object, purifying and inactivating the influenza virus through sucrose density gradient centrifugation, immunizing alpaca by taking the influenza virus as an immunogen, and screening by utilizing a phage display technology to obtain a high-affinity spectral anti-avian influenza virus NA protein nano antibody. Animal experiments show that the nano antibody has a good prevention effect when acting on A / Puerto Radio / 8 / 34 (H1N1) influenza virus infected C57 mice. Through preparation of the anti-influenza virus NA protein nano antibody, not only is a material provided for development of an H1N1 influenza virus diagnostic reagent, but also a thought is provided for identification of H1N1 subtype influenza virus epitope and vaccine design.

The application belongs to the technical field of biology, and discloses a preparation method of a Salmonella typhimurium flagellin and Senecavirus antigen fusion protein. The application selects Escherichia coli Rosetta (DE3) as a host, fuses a Salmonella typhimurium flagellin gene and a Senecavirus antigen gene, optimizes codons, and then clones the fusion protein into a pET-28a (+) vector, so that the obtained fusion protein can keep the adjuvant activity of the flagellin, improve the solubility and expression level of VP2, and the yield can reach 40 mg / L, thereby greatly reducing the expression and purification process cost. The fusion protein provided by the application can activate the TLR5 path and activate mouse macrophages, and the production process is simple and low in cost, so that the application has important significance for the research and production of Senecavirus subunit vaccines.

Abstract The present disclosure provides a method for vaccinating a subject against a mucosal virus 5 infection, comprising administering to the subject an immunologically effective amount of an intranasal booster, wherein the intranasal booster comprises detoxified Escherichia coli labile toxin (LT) and an antigen from the mucosal virus, and wherein the subject has been previously primed. An intranasal vaccine composition comprising an immunologically effective amount of a mucosal virus antigen adjuvanted with a detoxified Escherichia coli labile toxin (LT) is also .0 provided. ~22~ Sep 2023 Abstract 5 2023237105 27 ~22~

1. The name of the design product: kit (virus antigen detection). 2. The use of the design product: for containing each component of the kit for detecting avian leukosis virus. 3. The design points of the design product: the combination of shape, pattern and color. 4. The picture or photo that best shows the design points: perspective view 1. 5. The design for which protection is sought contains color.

The invention relates to a Chikungunya virus antigen and dengue virus antigen detection kit, a preparation method and a detection method. The kit comprises a chikungunya virus antibody marked by quantum dot microspheres, a dengue virus antibody marked by quantum dot microspheres, a sample loading solution and immunochromatography detection test paper. The kit and the detection method based on the fluorescence immunochromatography are high in sensitivity, strong in specificity and good in stability, can realize synchronous quantitative detection of chikungunya virus antigen and dengue virus antigen, effectively improve the detection efficiency, are simple and efficient in detection operation process, can report a result within 15 minutes, are suitable for on-site rapid detection, and have good application prospects. And a new means is provided for prevention, control, diagnosis and treatment of chikungunya virus and dengue virus.

The application discloses a high-recognition and low-scattering quantum dot tubular assembly structure immunochromatography probe and a preparation method and application thereof, and first prepares a nickel-hydrazine complex nanorod, performs etching to obtain a one-dimensional hollow tubular silicon dioxide nanotube, performs mercapto-modification, constructs an oil-soluble tubular assembly through multi-layer assembly of quantum dots, transfers the assembly to an aqueous solvent through an efficient alkylsilane phase transfer strategy, deposits a thin and dense silicon oxide layer on the surface of the assembly to protect the assembly, and simultaneously performs carboxylation and coupling of a novel coronavirus antigen N protein antibody based on the silicon oxide layer to obtain a fluorescent probe. The one-dimensional hollow tubular material is used as a carrier of a signal tag, and due to double optimization of signal amplification effect and immunoreaction efficiency, the sensitivity of a lateral flow immunochromatography platform is improved, and important scientific basis is provided for early discovery, early treatment and early prevention and control of virus infection.

The utility model provides a fish multi-virus antigen joint detection kit, which relates to the technical field of antigen detection, and comprises a plurality of outer shells, each outer shell is provided with a connecting assembly used for connecting two outer shells together, the top of each outer shell is provided with an observation window and a sample adding hole, and the observation window is provided with a plurality of through holes. One end of each outer shell is open, an inner shell is detachably installed in each outer shell in a sliding mode, a drawing handle is fixedly installed at the outer end of each inner shell, the free end of each drawing handle extends out of the corresponding outer shell, and a locking assembly is arranged between the inner end of each inner shell and the other end of the corresponding outer shell. According to the fish virus detection kit, the number of the outer shells and the types of the detection test strips can be freely combined according to the number and the types of fish viruses to be detected, and waste of the outer shells and the detection test strips is avoided.

The invention discloses a recombinant FCV antigen and a construction method and application thereof. The construction method of the recombinant FCV antigen comprises the following steps: fusing a T cell epitope coding sequence derived from a non-structural protein NS7 of FCV with a coding sequence of a SpyTag peptide fragment through a coding sequence of a linker, and cloning to a baculovirus transfer vector to obtain a recombinant plasmid; and finally, integrating the T cell epitope coding sequence into Bacmid through Tn7 transposition to finally obtain the recombinant FCV antigen. According to the invention, NS7 is selected as a core immunogen to guide an immune system to generate high cellular immune response, so that the defect of an existing vaccine in removing viruses in cells is overcome; meanwhile, T cell epitopes with specificity are selected from the sequence of NS7 as immunogens, so that the variability of antigens among different strains and immune escape caused by virus antigen drift can be avoided, and wider-spectrum protection is provided.

The application discloses a kind of NbP1 single-domain antibody, TAT-NbP1 fusion single-domain antibody and purposes thereof, belong to biological medicine technical field.The NbP1 single-domain antibody of the application is used to specifically bind new coronavirus PLpro antigen, the NbP1 single-domain antibody is composed of framework region FR and three complementarity determining regions CDR1, CDR2 and CDR3;The amino acid sequence of CDR1 is as shown in SEQ ID NO.1, the amino acid sequence of CDR2 is as shown in SEQ ID NO.2, the amino acid sequence of CDR3 is as shown in SEQ ID NO.3.TAT-NbP1 fusion single-domain antibody is the fusion protein of NbP1 single-domain antibody and HIV-1 virus TAT peptide segment.The NbP1 single-domain antibody and TAT-NbP1 fusion single-domain antibody provided by the application have both antiviral and anti-inflammatory activities, and are safe, which provides a new idea for treating SARS-CoV-2 infection and developing anti-SARS-CoV-2 drugs.

The invention belongs to the technical field of biology, and particularly relates to an antigen stabilizer, a preparation method and application. The invention provides an antigen stabilizer, which comprises the following components by mass concentration: 8-9 g / L of NaCl, 0.2-1.5 g / L of enzyme stabilizer and 5-6 g / L. The NaCl in the antigen stabilizer stabilizes a buffer system by adjusting osmotic pressure to prevent antigen damage; the enzyme stabilizer can stabilize the antigen and maintain the activity of the antigen; bovine serum albumin serves as a reaction stabilizer of enzyme, and decomposition and non-specific adsorption of the enzyme are prevented. The antigen stabilizer is mixed with a virus antigen for preservation, the HA titer of the virus antigen and the HA titer of a freeze-dried antigen have no obvious difference, but the antigen preservation process is simple, the stability and the specificity are good, and the heat tolerance of the antigen can be improved.

This invention provides a broad-spectrum non-neutralizing antibody against foot-and-mouth disease virus (FMD) and its application in the preparation of reagents that enhance the production of neutralizing antibodies, belonging to the field of antibody technology. The FMD virus broad-spectrum non-neutralizing antibody has the amino acid sequence of its heavy chain variable region as shown in SEQ ID NO:1 and the amino acid sequence of its light chain variable region as shown in SEQ ID NO:2. This invention utilizes single B-cell antibody technology to screen and obtain a porcine broad-spectrum non-neutralizing monoclonal antibody SP1C6, which can recognize a conformational epitope on VP2. The broad-spectrum non-neutralizing antibody SP1C6 increases the level of neutralizing antibodies induced by FMD virus in pigs by blocking the non-neutralizing epitopes of the FMD virus antigen.

The invention discloses an influenza vaccine reagent and a preparation method thereof, and relates to the technical field of biological medicines. The preparation method comprises the following steps: dissolving soybean lecithin and cholesterol in a mixed solvent of ethanol and tert-butyl alcohol to form a lipid membrane, hydrating the lipid membrane, and performing multi-step extrusion and filtration to obtain a sterile blank liposome; then encapsulating the tetravalent influenza antigen into the lipidosome; and then adding a composite freeze-drying protective additive composed of a polyvinyl alcohol grafted polysaccharide polymer and L-proline, and freeze-drying to obtain the liposome vaccine freeze-dried powder. The core of the invention is that the freeze-drying protective agent can significantly maintain the integrity of the liposome structure and the immunocompetence of the virus antigen in the freeze-drying process. The final product is quick to redissolve, has high encapsulation efficiency, excellent stability and strong immunogenicity, and is particularly suitable for constructing efficient and stable tetravalent influenza vaccines.

The invention relates to the technical field of genetic engineering, in particular to Encapsulin fusion protein for expressing foot and mouth disease virus epitopes and application of the Encapsulin fusion protein in preparation of subunit vaccines. The invention discovers that different foot-and-mouth disease virus antigen epitopes are inserted among the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids of an Encapsulin protein fragment subjected to amino acid sequence modification, and / or the 62nd to 63rd positions, the 124 to 125th positions, the 138 to 139th positions and the 239th to 240th positions of amino acids are replaced by different foot-and-mouth disease virus antigen epitopes; efficient and soluble expression of a target antigen in escherichia coli can be realized, and protein cage nano antigen particles are successfully self-assembled; the protein nano antigen particle can induce a widely neutralized foot-and-mouth disease virus antibody, improves the immune efficacy, and has the potential of becoming a broad-spectrum foot-and-mouth disease vaccine.

Provided herein are serial vaccination methods to induce an immune response against a pathogen (e.g., Beta coronavirus) comprising administering a first composition comprising a nucleic acid encoding a first antigen (e.g., a first Beta coronavirus antigen) and administering a second composition comprising a nucleic acid encoding an second antigen (e.g., a second Beta coronavirus antigen), and wherein the first composition and / or the second composition comprises an adjuvantation system comprising a mannan (e.g., a plant mannan or a fungal mannan).

The invention provides a bivalent vaccine which comprises a rabbit hemorrhagic syndrome virus antigen, a rabbit hepatitis E virus antigen and a microbial freeze-dried slow-release agent, and provides a preparation method which comprises the following steps: culturing the rabbit hepatitis E virus by using passage cells, obtaining the rabbit hepatitis E virus antigen, inoculating the rabbit hemorrhagic syndrome virus, and carrying out freeze-drying on the rabbit hemorrhagic syndrome virus. A rabbit hemorrhagic syndrome virus antigen is obtained, the rabbit hemorrhagic syndrome virus antigen and a rabbit hepatitis E virus antigen are mixed in proportion, a freeze-drying protective agent is supplemented, and the bivalent vaccine is obtained. The invention further provides an application experiment result of the compound, and the compound is used for preventing or treating rabbit hemorrhagic syndrome and rabbit hepatitis E. According to the invention, the two antigens are proportioned properly, so that the prepared vaccine at least achieves the efficacy of preventing and controlling immune epidemic diseases. The bivalent vaccine provided by the invention can prevent two diseases by one injection, reduce immune stimulation, continuously enhance the immune effect of a body, promote the body to generate better immune response, reduce the immune cost, simplify the immune procedure, and is more economical and reliable.

The invention relates to the technical field of biological medicine and vaccine preparation, and discloses a preparation method of a tetravalent influenza virus split vaccine, and the preparation method comprises the following steps: inoculating four influenza viruses into a chick embryo, culturing, harvesting allantoic fluid, and concentrating; centrifugally purifying through a sucrose density zone, and adding a cracking agent for cracking; removing the cracking agent from the cracking solution through chromatographic column chromatography, and then adding an inactivating agent for inactivating and removing the inactivating agent; according to the method disclosed by the invention, a process route of firstly splitting purification and then inactivation in combination with dual purification of centrifugation and chromatography is adopted, so that the problem of impurity cross-linking caused by an inactivator in a traditional process is effectively avoided, and residues of ovalbumin and splitting agents are deeply removed; and the natural conformation of the virus antigen is retained to the greatest extent. The obtained vaccine is extremely low in impurity content, has excellent safety and high immunogenicity, and can effectively expand the immune protection range and enhance the population immune barrier.

The invention discloses an akabane disease virus monoclonal antibody with virus neutralizing activity and a colloidal gold immunochromatography test strip prepared from the akabane disease virus monoclonal antibody, and belongs to the technical field of biology. The monoclonal antibody is secreted by a hybridoma cell strain with the preservation number of CGMCC (China General Microbiological Culture Collection Center) NO.45859, and is named as 1H6. The monoclonal antibody provided by the invention can specifically recognize AKAV N protein and can neutralize akabane disease virus. A purified monoclonal antibody 1H6 is coupled with gold particles, a rabbit anti-AKAV polyclonal antibody is coated on an NC membrane to serve as a detection T line, a goat anti-mouse IgG antibody is coated on an NC membrane to serve as a quality control C line, the colloidal gold immunochromatography test strip for detecting akabane disease viruses is constructed, and the colloidal gold immunochromatography test strip can be used for detecting akabane disease virus antigens. The method has the advantages of no need of professionals, simplicity in operation, high detection sensitivity and simple and convenient operation requirements, can meet rapid and mass screening detection of grassroots enterprises and public institutions, and can also be used for detection analysis such as scientific research and the like.

The application relates to a sample processing liquid for respiratory virus antigen detection and a preparation method thereof, which comprises a phosphate buffer, 0.05-0.5 g / L sodium caseinate, 1-20 g / L bovine serum albumin, 10-50 mL / L surfactant, 1-10 g / L guanidine hydrochloride, 3.72-37.2 g / L ethylenediaminetetraacetic acid disodium salt dihydrate solution, 1-5 mL / L CL preservative, 1-5 mL / L BND bacteriostatic agent and 900-988 mL / L sterile deionized water; and the application has the advantages of good sample stability.

The present application relates to a linear covalently closed DNA vaccine, comprising a plasmid vector containing an IHNV virus antigen expression unit, the sequence of the antigen expression unit is shown as SEQ ID NO. 1, and the DNA structure is in the form of linear end covalently closed form. The present application also relates to a preparation method and application of the linear covalently closed DNA vaccine. Compared with the traditional DNA vaccine, the linear covalently closed DNA vaccine has no redundant bacterial-derived nucleic acid sequence, and has good safety and effectiveness for the prevention and treatment of rainbow trout infectious hematopoietic necrosis.

The present application relates to the technical field of biological medicine, and particularly relates to a fusion protein and application thereof in preparation of a product for treating or preventing hepatitis B virus. The present application takes preS1 as a core antigen component and takes an improved IgM as a basic skeleton to obtain a preS1-IgM monomer, and then connects the preS1-IgM monomer through a J chain to obtain a fusion protein. The fusion protein is taken as an active component to construct a therapeutic vaccine, which can effectively stimulate an anti-preS1 antibody response and synergistically activate a Th1 / Th2 immune response. Experiments show that the vaccine alone can significantly reduce the serum HBsAg, HBV DNA and intrahepatic virus antigen levels of a chronic HBV infection model, and realize seroconversion of part of the animals. When the vaccine is used in combination with entecavir, a remarkable synergistic effect is exhibited. The vaccine significantly improves the therapeutic effect without causing significant liver damage, and provides an innovative immunotherapy with both prevention and treatment functions for chronic hepatitis B treatment.

The invention provides a method for preparing a Newcastle disease virus antigen by a cell suspension culture process, and relates to the technical field of virus antigen and vaccine preparation. The suspension culture method comprises the following steps: inoculating full-suspension Newcastle disease virus production cells into an F807k basal culture medium according to a certain density for cell culture, adding an NF01d supplementary culture medium after the cell culture is performed for 70-74 hours, adding an F808Vb supplementary culture medium after the cell culture is performed for 94-98 hours, inoculating Newcastle disease virus according to a virus inoculation amount of 0.1-0.5%, and culturing for 20-30 hours. And 38-42 hours after virus inoculation, adding the NF01d supplementary culture medium again, and expressing the Newcastle disease virus antigen at 28-38 DEG C. According to the optimized full-suspension culture process, higher antigen expression quantity can be obtained, the virus yield is improved, the hemagglutination titer of the obtained Newcastle disease virus antigen reaches 12log2 for the first time, and the protective efficacy is improved.

The application provides a test strip for detecting antibodies of a fever with thrombocytopenia syndrome virus antigen, a preparation method and application thereof. A pair of antibodies against the fever with thrombocytopenia syndrome virus antigen are screened, and a test strip is prepared based on the pair of antibodies, wherein the detection limit of the test strip is as low as 0.025 ng / mL, and the test strip has high specificity.